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Abstract
IMPORTANCE—Large patient cohorts are necessary to validate the efficacy of transoral robotic
surgery (TORS) in the management of head and neck cancer.
OBJECTIVES—To review oncologic outcomes of TORS from a large multi-institutional
collaboration and to identify predictors of disease recurrence and disease-specific mortality.

Author Manuscript

DESIGN, SETTING, AND PARTICIPANTS—A retrospective review of records from 410
patients undergoing TORS for laryngeal and pharyngeal cancers from January 1, 2007, through
December 31, 2012, was performed. Pertinent data were obtained from 11 participating medical
institutions.
INTERVENTIONS—Select patients received radiation therapy and/or chemotherapy before or
after TORS.
MAIN OUTCOMES AND MEASURES—Locoregional control, disease-specific survival, and
overall survival were calculated. We used Kaplan-Meier survival analysis with log-rank testing to
evaluate individual variable association with these outcomes, followed by multivariate analysis
with Cox proportional hazards regression modeling to identify independent predictors.

Author Manuscript

RESULTS—Of the 410 patients treated with TORS in this study, 364 (88.8%) had oropharyngeal
cancer. Of these 364 patients, information about post-operative adjuvant therapy was known about
338: 106 (31.3) received radiation therapy alone, and 72 (21.3%) received radiation therapy with
concurrent chemotherapy. Neck dissection was performed in 323 patients (78.8%). Mean followup time was 20 months. Local, regional, and distant recurrence occurred in 18 (4.4%), 15 (3.7%),
and 10 (2.4%) of 410 patients, respectively. Seventeen (4.1%) died of disease, and 13 (3.2%) died
of other causes. The 2-year locoregional control rate was 91.8% (95% CI, 87.6%-94.7%), diseasespecific survival 94.5% (95% CI, 90.6%-96.8%), and overall survival 91% (95% CI,
86.5%-94.0%). Multivariate analysis identified improved survival among women (P = .05) and for
patients with tumors arising in tonsil (P = .01). Smoking was associated with worse overall allcause mortality (P = .01). Although advanced age and tobacco use were associated with
locoregional recurrence and disease-specific survival, they, as well as tumor stage and other
adverse histopathologic features, did not remain significant on multivariate analysis.

Author Manuscript

CONCLUSIONS AND RELEVANCE—This large, multi-institutional study supports the role of
TORS within the multidisciplinary treatment paradigm for the treatment of head and neck cancer,
especially for patients with oropharyngeal cancer. Favorable oncologic outcomes have been found
across institutions. Ongoing comparative clinical trials funded by the National Cancer Institute
will further evaluate the role of robotic surgery for patients with head and neck cancers.
In 2015 nearly 60 000 patients in the United States will be diagnosed as having head and
neck cancer (HNC).1 Despite decreasing smoking rates,2 oropharyngeal cancer is increasing,
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especially in men, and appears related to high-risk human papillomavirus (HPV).3 In a
population-based study4 that used the Surveillance, Epidemiology, and End Results database
from 1988 to 2004, the incidence of HPV-positive cancers increased by 225%, whereas the
incidence of HPV-negative cancers decreased by 50%. The HPV-associated oropharyngeal
cancers have a better overall prognosis when compared with HPV-negative cancers and tend
to present with smaller primary tumor burden.5 In addition, HPV may be associated with a
surprisingly few nonoropharyngeal cancers in the larynx and pharynx.6
Excluding the oral cavity, patients with HNC have typically been treated with radiation with
or without chemotherapy because of the potential morbidities associated with traditional,
transmandibular, or transcervical open approaches. Because of the changing epidemiology
of this disease2,3 and concerns about the late toxic effects of radiation,7 the role of primary
surgery has been revisited.

Author Manuscript

In 2005, two groups8,9 presented the first experiences in robotic head and neck surgery. The
term transoral robotic surgery (TORS) was coined by Weinstein et al10 at The University of
Pennsylvania, and since then many single institutions have found that TORS is safe and
feasible and has good functional outcomes.10-13 In 2009, the US Food and Drug
Administration approved the use of the da Vinci Robotic Surgical System for transoral
otolaryngologic procedures, including selected benign and malignant T1 to T2 tumors.14,15
Although several institutions have reported oncologic results after TORS,10-13,16-24 many of
these reports are limited by small numbers, limited follow-up, or heterogeneity within the
study population.

Author Manuscript

To better understand the oncologic outcomes after TORS for HNC, larger, more
homogenous studies are needed. We report the results of a multi-institutional working group
study to better evaluate the oncologic outcomes, to better understand patterns of recurrence
and mortality, and to identify the risk factors associated with each. A better understanding of
these outcomes might serve as the basis for future prospective studies.

Methods
Patients

Author Manuscript

For selected patients with squamous cell carcinoma of the head and neck arising from the
posterior oral cavity, oropharynx, larynx, and hypopharynx, TORS was performed at 11
institutions from January 1, 2007, through December 31, 2012. Participating institutions
included Albert Einstein College of Medicine, Université Catholique de Louvain at Dinant
Godinne Namur, Memorial Sloan-Kettering Cancer Center, New York Head and Neck
Institute, Mount Sinai Medical Center, Stanford University, University of Alabama at
Birmingham, University of California, San Francisco, Mayo Clinic, Rochester, Minnesota,
The University of Texas MD Anderson Cancer Center, University of Pittsburgh Medical
Center, Veterans Affairs Pittsburgh Healthcare, and Yonsei University School of Medicine.
This study was endorsed by the Research Committee of the American Head and Neck
Society in 2011.
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Treatment specifics for patients were institution dependent and usually determined in
consultation with a multidisciplinary tumor board. In general, surgery was performed using a
da Vinci robotic system (Intuitive Surgical Inc) with techniques previously
described.10,11,13,22,25 Surgical candidates generally had smaller volume tumors amenable to
surgery, although large tumors were not necessarily a contraindication for surgery and were
not excluded from the analysis. Access to the oropharynx was achieved with the FeyhKastenbauer, Weinstein-O’Malley-Feyh-Kastenbauer, Crowe-Davis, Laryngeal Advanced
Retractor System, or Dingman retractor. Tumors were resected using oncologic principles
with attempts to achieve negative surgical margins on frozen-section pathologic analysis.
The institutions within this study used differing designations to define negative and/or close
margins. Some centers used a 2 mm cutoff while others used 5 mm. A close margin was
defined as less than a negative margin but without tumor at the cut edge of the specimen on
final pathology, which was defined as a positive margin. Neck dissections were performed
for clinically positive neck disease and patients at high risk for occult nodal disease.
In this multicenter review, postoperative adjuvant therapy was not standardized and was
given in accordance with local institutional multidisciplinary tumor board recommendations.
Patients with adverse pathologic features after surgery received adjuvant treatment with
radiation alone or combined chemoradiation. Adverse pathologic features included positive
or close margins, extracapsular nodal spread, lymphovascular invasion, perineural invasion,
multiple positive lymph nodes, or advanced T and/or N classification. Radiotherapy and
chemotherapy protocols varied by institution. Radiation dosage varied based on the presence
of persistent disease, high risk of disease, and low risk of disease.

Author Manuscript

Data Collection
Institutional review board approval for a waiver of consent for this retrospective review was
obtained for each institution. De-identified data were pooled. Outcomes were retrospectively
collected using a standardized data collection form across institutions. Outcomes pertaining
to patient demographics, disease, treatment, and oncologic outcomes were collected.
Individual institutions collected data, and analysis was pooled across institutions.
Statistical Analysis

Author Manuscript

Data were analyzed using SPSS statistical software, version 20 (SPSS Inc), and Stata SE,
version 13 (StataCorp). Descriptive statistics were used to summarize data where applicable.
Kaplan-Meier methods were used for oncologic outcomes with the log-rank test to compare
recurrence and survival outcomes between groups. Multivariate analysis was performed to
identify independent risk factors for recurrence and survival using Cox proportional hazards
regression models. We selected potential independent risk factors for multivariate analysis
based on their significance in univariate testing. For locoregional recurrence, these risk
factors included age older than 60 years, a positive smoking history, positive margins, and
oropharyngeal wall or faucial arch subsite. For overall survival, multivariate analysis
included the risk factors of age older than 60 years, male sex, smoking history,
oropharyngeal wall or faucial arch subsite, and tongue base subsites.
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Results
Patients
In this multicenter study, TORS was performed on 410 patients, most of whom were men
(338 [82.4%]) with tumors classified as T1 (170 [41.5%]) or T2 (172 [42.0%]). TORS was
most often selected for patients with oropharyngeal cancer (364 [88.8%] of 410): 45.4%
arising in the tonsil, 31.7% in the tongue base, 8.0% in or across the faucial arch or
oropharyngeal walls, and 3.4% in the soft palate. A more complete clinical and demographic
profile of the study population is presented in Table 1. The mean follow-up was 20 months
(range, 1-74 months).

Author Manuscript

Smoking status was known for 338 (82.4%) of 410 patients. Of these, 224 (66.3%) had
smoked at some point in their lives. Of the smokers, 10.3% were pipe or cigar smokers,
14.7% smoked 10 pack-years or less, 27.2% smoked 11 through 19 pack-years, 28.1%
smoked 20 through 40 pack-years, and 19.6% smoked more than 40 pack-years. Alcohol use
was common in the study population: 166 (40.5%) actively consumed alcohol, 50 (12.2%)
had quit, and 86 (26.3%) did not consume alcohol. Of these, 55.0% currently consumed
alcohol, 16.6% had quit, and 28.5% had no history of alcohol use.
The HPV status was known in 229 (55.9%) of 410 patients. Of these, 159 patients (69.4%)
were HPV positive by HPV polymerase chain reaction assay or in situ hybridization
techniques. The p16 status was known for 219 (53.4%) of 410 patients. Of the 219 patients
with known p16 status, 158 (72.1%) were p16-positive by immunohistochemical staining.
Treatment

Author Manuscript

All patients underwent TORS for resection of the primary tumor. Eleven (2.7%) of 410
patients previously received radiation alone or chemoradiation and underwent TORS as a
salvage procedure. Of the 393 patients (95.9%) who had known margin status, 39 (9.9%)
had positive margins.

Author Manuscript

Four hundred patients had information regarding whether a neck dissection was performed.
Neck dissection was performed in 323 patients (78.8%). Of those who underwent neck
dissections, 226 (70.0%) underwent the dissection concurrently with TORS surgery, and 97
(30.0%) underwent neck dissection in a staged fashion. Adjuvant treatment data were
unknown for 72 (17.6%) of 410 patients. Of those with known adjuvant treatment status,
TORS alone was performed in 160 (47.3%) of 338 patients, 106 (31.4%) of 338 underwent
adjuvant radiotherapy, and 72 (21.3%) of 338 patients underwent adjuvant chemoradiation.
Therefore, we had available adjuvant treatment data on 338 patients (82.4%), of whom
52.7% received adjuvant therapy.
Recurrences
Forty-three patients (10.5%) experienced recurrences. Thirty-three patients (8.0%)
experienced local or regional recurrences. Ten patients (2.4%) experienced distant
metastases. The median time to locoregional recurrence was 16.4 months. Twenty-one
patients (5.1%) experienced recurrences within the first 2 years after surgery. In patients
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experiencing recurrences, 8 of 130 tongue base primary tumors (6.2%), 5 of 186 tonsil
primary tumors (2.7%), 6 of 34 oropharyngeal wall or faucial arch primary tumors (17.6%),
and 2 of 14 soft-palate primary tumors (14.3%) recurred. Tumor recurred in 13 (8.1%) of
160 patients treated with TORS alone without adjuvant treatment.

Author Manuscript

The 2-year and 3-year locoregional control rates for the entire cohort were 91.8% (95% CI,
87.6%-94.7%) and 88.8% (95% CI, 83.5%-92.4%) (Figure 1). Because 88.8% of the
patients in our cohort presented with oropharyngeal primary tumors, we evaluated
locoregional control by oropharyngeal subsite, HPV status, and p16 status (Figure 1). Tonsil
primary tumors had the highest rate of locoregional control by log-rank testing (P = .01). We
did not observe differences in locoregional control associated with known HPV or p16
status. The greatest difference in locoregional control was seen when comparing patients
with positive margins and those with clear margins (P = .001) (Figure 1). At 2-year followup, the locoregional control rate for patients with positive margins during TORS was 78.6%
compared with 92.9% when surgical margins were negative. At 3-year follow-up, the
locoregional control rate for patients with positive margins during TORS was 63.5%
compared with 91.2% when surgical margins were negative. Risk factors for locoregional
recurrence are outlined in Table 2. In univariate analysis, older age, smoking status,
oropharyngeal wall or faucial arch primary tumor site, and positive margins were risk factors
for disease recurrence. Tonsil primary site predicted a lower risk of recurrence compared
with all sites. In multivariate analysis, none of these predictors remained a significant
predictor of recurrence (Table 3). Although comparison of oropharyngeal subsites revealed
differences in locoregional recurrence rates, we did not observe differences in recurrence
rates between overall head and neck sites (ie, oropharynx, oral cavity, supraglottic larynx,
hypopharynx).

Author Manuscript

Survival
Overall, there were 30 deaths (7.3%) in the cohort. There was a single mortality related to
surgery due to postoperative hemorrhage on the night of surgery. Seventeen patients (4.2%)
died of their disease, and 13 patients (3.2%) died without any evidence of disease. Of those
who died without any evidence of disease, 8 died of unknown causes, and 4 died of causes
unrelated to cancer, including cardiac arrest (n = 1), cerebrovascular accident (n = 1),
complication of gastrostomy tube placement (n = 1), and ruptured aortic aneurysm (n = 1).

Author Manuscript

The 2- and 3-year overall survival rates were 91% (95% CI, 86.5%-94.0%) and 87.1% (95%
CI, 81.4%-91.2%), respectively (Figure 2). The 2- and 3-year disease-specific survival rates
were 94.5% (95% CI, 90.6%-96.8%) and 92.5% (95% CI, 87.8%-95.5%), respectively.
Again, because most patients presented with oropharyngeal primary tumors, we compared
overall and disease-specific survival rates based on HPV and p16 status. No significant
differences were observed. On univariate analysis, risk factors for death of any cause
included age, male sex, tobacco history, and oropharyngeal wall or faucial arch primary site
(Table 2). On multivariate analysis, only tobacco smoking history predicted worse overall
survival, whereas tonsil primary site was associated with improved overall survival (Table
3). Unfortunately, tobacco smoking as a negative risk predictor may have been confounded
by limited HPV data in this study; thus, we were cautious to draw any conclusion about the
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influence of tobacco itself. We did not perform a survival analysis comparing overall head
and neck sites because no differences in locoregional recurrence rates were observed
(eFigure in the Supplement). Furthermore, because most patients (88.8%) in this study had
oropharyngeal primary tumors, a robust survival comparison that included
nonoropharyngeal sites was not possible.

Discussion

Author Manuscript

To our knowledge, this study reports the largest series of patients undergoing TORS for the
treatment of HNC. Our collaboration across 11 medical centers draws on a diverse
experience to further elucidate the role of TORS across various multidisciplinary treatment
paradigms. Informative data on adjuvant treatment regimens for most of these patients were
available to comprehensively review patients’ treatment plans. The findings from the present
study support the use of TORS as a treatment alternative for select HNCs. Ongoing clinical
trials will better help delineate its role.

Author Manuscript

This study presents a broad description of TORS applied to the treatment of HNC. However,
as reported, 88.8% of patients had oropharyngeal primary tumors. Our rationale for the
inclusion of other sites (ie, supraglottic larynx, hypopharynx, posterolateral oral cavity) was
to determine where TORS fits into the multidisciplinary treatment paradigm across
institutions. On the basis of this experience, TORS appears to play the greatest role in the
multidisciplinary management of patients with oropharyngeal cancer. Furthermore, we were
able to evaluate morbidity and mortality from postoperative bleeding experienced by the
various participating centers. Fatal post-operative hemorrhage was encountered in 1 (0.2%)
of 410 patients. This death occurred the night of surgery in a patient who had previously
received preoperative chemotherapy (cetuximab) but no radiation therapy. This is an
important adverse event relevant to all sites amenable to transoral endoscopic head and neck
surgery. Patients should be counseled about this rare but catastrophic surgical complication
but reminded that primary chemoradiation protocols carry an approximately 2% treatmentrelated mortality risk.5

Author Manuscript

The pathophysiologic basis of oropharyngeal cancers has changed markedly during the past
several decades. In a review of the National Cancer Institute’s Surveillance, Epidemiology,
and End Results database, Chaturvedi et al4 found that from the years 1973 to 2004 the
incidence of high-risk HPV-associated oropharyngeal cancers increased by 225%, whereas
HPV-negative cancers decreased by 50%. It is now estimated that more than 70% of
oropharyngeal cancers have evidence of an HPV infection. These virally mediated cancers
tend to present with smaller primary tumor volume and more advanced nodal disease.21,26,27
This changing pattern of the disease with fewer locally advanced tumors may then be more
amenable to surgical resection without rendering patients functionally disabled from highvolume resections. Indeed, of the 364 patients (88.8%) in this study treated for
oropharyngeal primary tumors, 314 had pathologic stage T2 or lower disease.
In this present study, 338 patients had available data regarding adjuvant therapy. Of these,
106 (31.3%) received radiation therapy alone and 72 (21.3%) received combined
chemoradiotherapy. In aggregate, 50.2% had N2a or greater nodal disease with negative
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primary margins or positive margins with any nodal status, both disease categories that
would commonly warrant at least adjuvant radiation therapy.
The early functional outcomes studies for TORS suggest good postoperative results with
early oral alimentation and limited long-term sequelae.7,11-13 In a prospective comparative
study,11 patients treated with TORS had significantly better eating ability and dietary intake
2 weeks after treatment compared with patients treated with chemoradiation. In addition,
surgical patients experienced a return of their oral dietary intake 1 year after surgery,
whereas patients treated with chemoradiation continued to have decreased oral diet as
assessed by the Performance Status Scale questionnaire. In the absence of persistent disease
after surgery, those who receive adjuvant radiotherapy do so at a reduced dose compared
with definitive therapy, which may reduce the early and late toxic effects of radiotherapy.28

Author Manuscript
Author Manuscript

With the emergence of TORS in the treatment of oropharyngeal cancer in the last decade,
reporting of oncologic results was relatively limited to informative but smaller cohort sizes.
Weinstein et al10 reported cancer oncologic results for 47 patients undergoing TORS for
oropharyngeal cancer. In their study, the 2-year disease-specific survival was 90%, and local
recurrences occurred in 2% of patients, regional recurrences in 4%, and distant metastases in
9%. White et al24 reported 1- and 2-year oncologic outcomes in a cohort that included all
head and neck sites (including larynx and oral cavity). Among the 89 patients included in the
analysis, there were 11 recurrences (3 local, 7 regional, and 1 distant) and an overall
recurrence-free survival rate of 86.5%. Genden et al17 reported oncologic results on 30
patients with head and neck squamous cell carcinomas treated with TORS. They described
an 18-month locoregional control rate of 91%, a disease-free survival rate of 78%, and an
overall survival rate of 90%. Moore et al16 followed up 66 patients for a minimum of 2 years
and reported a 2-year disease-specific survival rate of 95.1% and a recurrence-free survival
rate of 92.4%, with 3-year local and regional control rates of 97.0% and 94.0%, respectively.
More recently, Weinstein et al15 reported on the largest multicenter series of patients with
cancer undergoing TORS (N = 177), with the primary oncologic outcomes of interest being
margin status. Seven (4.3%) of 161 patients with available margin data had positive final
margins. In this largest reported series of patients with cancer undergoing TORS, similar
findings are observed: obtaining negative margins is feasible in most properly selected
patients. Low rates of positive margins in our current study also demonstrate favorable rates
of locoregional control and disease-specific mortality in a larger cohort of patients treated
with TORS.

Author Manuscript

Our results also compare favorably with oncologic outcome data for definitive radiotherapy.
Eisbruch et al29 and the Radiation Therapy Oncology Group described a locoregional
control rate of 91% for patients treated with accelerated hypo-fractionated intensitymodulated radiation therapy without chemotherapy for T1 and T2 oropharyngeal cancers
with N0 or N1 nodal disease. Garden et al30 found a locoregional control rate of 94%, a
recurrence-free survival rate of 88%, and an overall survival rate of 94% in a similar cohort
of patients treated with intensity-modulated radiation therapy for small primary disease.
Mendenhall et al31 found a 5-year local control rate of 93% for T1 and 91% for T2
oropharyngeal cancers treated with intensity-modulated radiation therapy. Sher et al32 found
similar results with a 3-year locoregional control rate of 97% and 79% for T1 and T2
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oropharyngeal cancers, respectively, treated with concurrent chemoradiotherapy or with
induction chemotherapy followed by concurrent chemoradiotherapy.
To our knowledge, this is the largest study reporting oncologic outcomes for oropharyngeal
cancers treated with TORS. The size of the cohort enabled us to better delineate patterns of
recurrence in this population and risk factors for recurrence. Overall, 43 patients (10.5%)
experienced a recurrence, with 17 patients (4.2%) dying of disease after treatment. No
independent predictors of recurrence remained significant in multivariate analysis although
positive margin status neared significance (P = .06). Positive margin status is a well-known
predictor of local recurrence in oropharyngeal cancer.33,34 In our study, there was a higher
incidence of positive margins in patients with oropharyngeal wall or faucial arch tumors;
however, only 34 of 410 patients had this primary subsite, making interpretation of these
results challenging.

Author Manuscript

Unfortunately, this registry study did not have adequate HPV status information for 181 of
410 patients (44.1%). This limits the ability to accurately compare oncologic outcomes
based on HPV status. Our finding that HPV-negative tumors did not have a higher likelihood
of recurrence or mortality compared with those with HPV-positive tumors requires further
validation. Cohen et al16 also did not observe a difference in locoregional control or survival
in patients with HPV-associated tumors treated with TORS. In our study, because most
patients had low primary tumor volume irrespective of HPV status, this factor may explain
why local control rates and overall survival did not differ based on HPV status. Ultimately,
our results indicate favorable oncologic outcomes for HPV-positive and HPV-negative
groups using a TORS approach.

Author Manuscript
Author Manuscript

There are limitations to this study. As a retrospective study, variability in reporting across the
centers and thus missing data elements pertaining to pathologic variables limit definitive
comparative analyses. As a result, many subgroup analyses may be underpowered to detect
significant differences. Only prospective studies with standardized end points and
subsequent pathologic analysis can circumvent this issue. In addition, with a mean follow-up
time of 20 months, the follow-up time may limit definitive conclusions about oncologic
outcomes after TORS. However, our results suggest that most recurrences occur within the
first 2 years. Last, the data collected here represent the results of 11 institutions with
expertise in TORS. The results may not necessarily be applicable to new adopters of this
technology because there is a learning curve to become technically facile. Future prospective
studies are needed to better delineate the role of TORS in oropharyngeal cancer35 and to
compare the functional outcomes of this approach and definitive radiotherapy. Results of
study 3311 from the Eastern Cooperative Oncology Group, a National Cancer Institute–
funded clinical trial in transoral endoscopic head and neck surgery, may help to further
elucidate the role of TORS within the HPV-positive oropharyngeal cancer. The present study
serves to support favorable oncologic results achieved with patients treated with TORS.

Conclusions
This large, multicenter collaborative study supports the role of transoral robotic head and
neck surgery within the multidisciplinary treatment paradigm for the treatment of HNC,
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especially for patients with oropharynx cancer. Pathologic staging obtained from TORS may
allow multidisciplinary teams to administer adjuvant therapy using a precision-medicine
approach. Favorable oncologic outcomes have been found across institutions. Ongoing
prospective clinical trials will provide further information regarding integrating robotic
surgery into a treatment algorithm for optimal patient care.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Locoregional Control (LRC) for Patients Treated With Transoral Robotic Surgery
(TORS)

Locoregional control by oropharyngeal subsite in all patients and pathologic margin status,
human papillomavirus (HPV) status, and p16 status in patients with oropharyngeal primary
tumors.
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Figure 2. Overall Survival (OS) and Disease-Specific Survival (DSS) for Patients Treated With
Transoral Robotic Surgery (TORS)

Overall survival and DSS in all 396 study patients with head and neck cancer.
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Author Manuscript

Patient and Tumor Characteristics
Characteristic
Age, mean (SD), y

a

Value (N = 410)
59.6 (10.8)

Sex
Male

338 (82.4)

Female

72 (17.6)

Smoking history

Author Manuscript

Yes

224 (54.6)

No

114 (27.8)

Unknown

72 (17.6)

Alcohol use history
Yes

166 (40.5)

No

86 (21.0)

Quit

50 (12.2)

Unknown

108 (26.3)

Subsite
Oropharynx

364 (88.8)

Author Manuscript

Supraglottic larynx

24 (5.9)

Hypopharynx

9 (2.2)

Posterolateral oral cavity

9 (2.2)

Other

4 (1.0)

Pathologic tumor stage

Author Manuscript

Tx

18 (4.4)

T0

12 (2.9)

T1

170 (41.5)

T2

172 (42.0)

T3

28 (6.8)

T4

10 (2.4)

JAMA Otolaryngol Head Neck Surg. Author manuscript; available in PMC 2016 September 12.

de Almeida et al.

Characteristic

Page 17

a

Value (N = 410)

Author Manuscript

Pathologic nodal stage
N0

120 (29.2)

N1

57 (13.9)

N2a

64 (15.6)

N2b

110 (26.8)

N2c

16 (3.9)

N3

7 (1.7)

Nx

36 (8.8)

Author Manuscript

Positive margins
Yes

39 (9.9)

No

354 (86.3)

Unknown

17 (4.1)

Close margins (1-5 mm)
Yes

86 (21.0)

No

170 (41.5)

Not specified

154 (37.6)

Author Manuscript

Perineural invasion
Yes

67 (16.3)

No

234 (57.0)

Not specified

109 (26.6)

Lymphovascular invasion
Yes

78 (19.0)

No

217 (52.9)

Not specified

115 (28.0)

Multiple nodal positivity

Author Manuscript

Yes

110 (26.8)

No

241 (58.8)

Unknown

59 (14.4)
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a

Value (N = 410)

Author Manuscript

Extracapsular spread
Yes

58 (14.2)

No

100 (24.4)

Unknown

252 (61.5)

HPV status (229 patients
tested)
Negative

70 (17.1)

Positive

159 (38.8)

Unknown

181 (44.1)

Author Manuscript

p16 positivity (219 patients
tested)
Negative

61 (14.9)

Positive

158 (38.5)

Unknown

191 (46.6)

Neck dissection
Yes

323 (78.8)

No

77 (18.8)

Unknown

10 (2.4)

Author Manuscript

Adjuvant treatment (338
patients)
Radiotherapy

106 (25.9)

Chemoradiotherapy

72 (17.6)

No adjuvant treatment
received

160 (39.0)

Unknown

72 (17.6)

Abbreviation: HPV, human papillomavirus.

a

Data are presented as number (percentage) of patients unless otherwise indicated.
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Table2

Author Manuscript

Factors Associated With Locoregional Control and Overall Survival (N=410)

2-Year Locoregional
Control, %

Factor

P Value for
Log-Rank
a
Test

2-Year Overall
Survival, %

P Value for
Log-Rank
a
Test

Age, y
<60

94.6

≥60

88.7

87.6
.01

.01
93.9

Sex
Male

91.8

89.1
.94

Author Manuscript

Female

.03

91.9

98.6

Yes

88.8

86.0

No

96.9

Smoking history

.01

.001
97.2

HPV
Positive

95.0

96.7
.52

Negative

.23

Author Manuscript

92.0

93.7

Positive

96.9

100

Negative

87.6

p16

.08

.13
94.9

Subsite
Tonsil vs all other

97.1

.01

95.4

.01

BOT vs all other

90.7

.99

92.1

.83

Oropharyngeal wall and faucial
arch vs all others

74.1

.001

81.8

.04

Soft palate vs all other sites

77.9

.19

100

.26

Author Manuscript

Positive margins
Yes

78.6

93.9
.001

No

92.9

.36
90.9

JAMA Otolaryngol Head Neck Surg. Author manuscript; available in PMC 2016 September 12.

de Almeida et al.

Page 20

2-Year Locoregional
Control, %

Author Manuscript

Factor

P Value for
Log-Rank
a
Test

2-Year Overall
Survival, %

P Value for
Log-Rank
a
Test

Perineural invasion
Yes

94.4

No

91.0

86.3
.82

.55
90.7

Lymphovascular invasion
Yes

100

88.6
.01

No

.94

89.2

90.0

T1-T2

91.7

90.1

T3-T4

96.1

Tumor stage

Author Manuscript

.50

.86
92.6

Nodal stage

Author Manuscript

N0

90.7

.16

91.0

.53

N1

93.6

.47

84.9

.12

N2a

94.7

.40

92.4

.72

N2b

100

.01

90.6

.88

N2c

100

.27

90.9

.68

N3

100

.47

100

.41

Nx

42.6

<.001

100

.52

None

86.6

.12

93.5

.58

Radiotherapy

98.9

.40

95.1

.14

Chemoradiotherapy

96.5

.16

81.0

.03

Adjuvant treatment

Abbreviations: BOT, base of tongue; HPV, human papillomavirus.

a

Log-rank test.
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Table 3

Author Manuscript

Multivariate Analysis of Risk Factors for Locoregional Recurrence and All-Cause Mortality
Factor

HR (95% CI)

a

P Value

Risk Factors for Locoregional Recurrence
Age >60 y

2.49 (0.90-6.92)

.08

Smoking history

3.60 (0.81-15.9)

.09

Positive margins

2.43 (0.92-6.47)

.07

Tonsil primary site

0.28 (0.08-1.00)

.05

Oropharyngeal wall, faucial wall primary site

2.51 (0.87-7.28)

.09

Age >60 y

1.76 (0.79-3.96)

.17

Female sex

0.18 (0.02-0.99)

.05

Smoking history

6.90 (1.57-28.9)

.01

Tonsil primary site

0.18 (0.07-0.65)

.01

Oropharyngeal wall, faucial wall primary site

0.91 (0.36-3.23)

.90

Tongue base primary site

0.53 (0.26-1.68)

.39

Author Manuscript

Risk Factors for All-Cause Mortality

Abbreviation: HR, hazard ratio.

a

Cox proportional hazards model.
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